LOG IN Directly Impacting Patient Care Today and Shaping the Future of Patient Care Tomorrow We are dedicated to a transformation in cancer care driven by the belief that the more we know about cancer’s molecular underpinnings, the better we can help physicians make the best treatment decisions for their patients. Through richer science, deeper insights, and stronger partnerships—we’re redefining the way cancer is treated. Advancing Cancer Care Together Every advancement we make today has the potential to help the next patient diagnosed tomorrow. Since our founding, we’ve made incredible progress—breakthroughs that have helped shift the treatment paradigm to directly impact patient care. Foundation Medicine, a leading decision insights company, is helping physicians connect their patients to the latest cancer treatment options—making precision medicine a reality for thousands. For Providers For Biopharma Partners For Patients More Than Numbers Our unique knowledge base, FoundationCore®, is one of the world's largest cancer genomic databases. It is designed to evaluate the genomic landscape across cancer types to better understand tumor biology, molecular biomarkers, and which treatments might work for which patients. This all helps researchers and biopharma companies develop new therapies, design better clinical trials, and advance precision medicine. 500k+ PATIENT SAMPLES PROFILED 65+ BIOPHARMA PARTNERS 500+ PEER-REVIEWED PUBLICATIONS Valuable Insights, Actionable Options Our tests help to identify the genomic alterations driving a patient's cancer and match them with relevant targeted therapies, immunotherapies, and clinical trial options. We also provide decision support services and technology solutions to help support patient care. Learn more about our products and services Patient Story Treating cancer means more than just dealing with the disease; it also means treating the whole person. Christine Bray, ovarian cancer survivor, shares her journey to remission after obtaining a Foundation Medicine comprehensive genomic profiling test. WE CONTINUE TO DRIVE FOR FUTURE BREAKTHROUGHS IN PATIENT CARE FoundationOne®Liquid CDx FoundationOne®Liquid CDx has been approved by the FDA as the only blood-based CGP companion diagnostic (CDx) for Tabrecta® (capmatinib). Our FDA-approved portfolio of both CGP tissue- and blood-based tests are now approved as the only CDx for Tabrecta® (capmatinib) in identifying advanced non-small cell lung cancer (NSCLC) patients having mutations that lead to METex14 skipping mutations and offers the highest number of CDx indications in NSCLC. LEARN MORE ABOUT FOUNDATIONONE LIQUID CDX Important Safety Information SELECT FoundationOne CDx FoundationOne Liquid CDx FoundationOne CDx PRODUCTS & SERVICES Our Tests Provider Services Biopharma Partner Services NEWS & EVENTS Press Releases Blog Events ABOUT US Our Story Leadership Team Careers CONTACT US LOGIN ORDER A TEST © 2021 FOUNDATION MEDICINE, INC. Legal & Privacy California Compliance Notice of Privacy Practices Licenses Update Cookie Preferences